Sartorius Stedim Biotech Introduces Advanced System for Agar and Membrane Transfer
Sartorius Stedim Biotech (SSB), a leading global supplier for the pharmaceutical and biotech industries, is introducing Microsart @media to complement Microsart @vance, a product line for microbiological quality control in these sectors.
Microsart @media are agar media dishes for microbial limits testing according to the USP (Chapter <61>) and EP (Chapter 2.6.12). They are pre-filled with various agar media types, such as Tryptic Soy Agar or R2A Agar, sterile packaged and ready-to-use in combination with Microsart @filter units. Moreover, the Microsart @media features an innovative patented lid that allows touch-free transfer of the filter membrane onto the media without using any tweezers. In addition, easy access to the colonies after incubation is given due to the liftable lid. The intelligent design and ease of use eliminates almost all handling mistakes.
The combination of Microsart @media and Microsart @filters introduce a brand-new agar and membrane transfer concept. Thanks to their concerted development the matching Microsart @media active lid fits perfectly onto the Microsart @filter base. The few steps required between sampling and incubation save time and labor, while delivering more reliable results. The touch-free membrane transfer eliminates membrane manipulation and handling, thereby minimizing a major source of secondary contamination.
Related News
-
News Novartis signs US$3.2 bn subcutaneous delivery deal with Alteogen
Swiss pharma giant secures access to Korean biotech's ALT-B4 hyaluronidase platform in milestone-heavy agreement, marking Alteogen's fourth major licensing deal of 2026 as competition intensifies in the subcutaneous drug delivery space.
-
News Women in Pharma: The philosophy of pharmaceutical leadership
In this latest instalment of our Women in Pharma series, we sit down with Clarissa Sowemimo-Coker, Chief Strategy Officer at Ambrose Healthcare and CPHI Middle East Advisory Board Member.
-
News The PSCI Supplier Partnership - Collaboration for Responsible Supply Chains
About the Pharmaceutical Supply Chain Initiative The Pharmaceutical Supply Chain Initiative (PSCI) is the leading, member-led association for pharmaceutical companies working collaboratively to build responsible supply chains. Founded in 2006 and es... -
News AstraZeneca shares plunge 8.9% after reports of BMS talks
Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem... -
News GSK announces £400 million investment in new Cambridge R&D centre
Pharmaceutical giant to establish flagship research facility on Cambridge Biomedical Campus as part of strategic pipeline acceleration
-
News The CPHI Sustainability Summit - Where Conversation Becomes Collaboration
The Report Was Never the Destination - “The future of pharmaceutical sustainability won’t be shaped by individual organisations working in isolation. It will be shaped by partnerships, shared expertise and the willingness to work diffe... -
News Trump's generic drug tariffs set to reshape global pharmaceutical supply chains
The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t... -
News Building Safer, More Responsible Pharmaceutical Supply Chains: PSCI Global Audit Insights
The Pharmaceutical Supply Chain Initiative (PSCI) has released its seventh annual Audit Findings Analysis Report, offering unprecedented insights into supplier practices across the global pharmaceutical and healthcare industry.With a record-breaking 24...